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Abstract 
A 20-year-old obese Thai woman with polycystic ovary syndrome and clinical stage I 
well-differentiated endometrial carcinoma denied surgical staging. Chest X-ray and 
magnetic resonance imaging of the whole abdomen suggested neither distance 
metastasis nor local invasion of the cancer. After 3 months of systemic progestin therapy 
with megestrol acetate (MA) 480 mg/day, the endometrial carcinoma persisted. The 
treatment was changed to a combination of levonorgestrel intrauterine system (LNG-IUS) 
and MA with a stepping-up from 160 to 480 mg/day. Complete remission was achieved 
at treatment month 9. Prevention of recurrence was provided using LNG-IUS plus MA 160 
mg/day. Endometrial surveillance using trimonthly transvaginal ultrasonography and 
endometrial biopsy suggested no recurrence for at least 24 months after remission. 
 
Introduction 
Endometrial carcinoma is one of the most common gynecologic malignancies. 
Although it is primarily a disease of postmenopausal women, 25% of patients are in the 
premenopausal period, and 3–5% are <40 years of age [1–3]. Obesity and chronic 
anovulation are major risk factors of endometrial carcinoma in young women [4, 5]. 
These conditions are associated with unopposed estrogen status, which induces 
endometrium proliferation resulting in increased risks of endometrial hyperplasia and  
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carcinoma. The standard treatment of endometrial carcinoma is surgical staging, which 
would destroy the reproductive function. Alternatively, conservative treatment with high-
dose progestin is feasible in young women who wish to retain their reproductive function 
[3, 6–9], as cancers in these women are usually well-differentiated and in an early stage at 
the time of diagnosis [1, 10]. Unfortunately, some reports showed that obese patients may 
not optimally respond to either systemic or local progestin therapy [11, 12], but a 
combination of both therapies may intensify the therapeutic effect [13]. In this report, we 
present a case of clinical stage I well-differentiated endometrial carcinoma in an obese, 
young Thai woman with polycystic ovary syndrome (PCOS) treated with a combination 
of levonorgestrel intrauterine system (LNG-IUS) and an oral progestin, megestrol acetate 
(MA). 
Case Report 
A 20-year-old Thai woman presented with oligomenorrhea since menarche. Her last menstrual 
period had occurred 2 months prior to the visit to our clinic. She had never been on treatment for her 
menstrual abnormality. She denied having had any medical diseases. She was obese (body mass index of 
28.7 measured in kg/m
2) with central obesity (waist circumference of 100 cm). She had normotensive 
blood pressure and acanthosis nigricans, but she had no clinical hyperandrogenism. Ultrasonography 
demonstrated polycystic ovaries, a normal-sized uterus and hyperechoic endometrium with a thickness 
of 19.8 mm. Blood tests for prolactin, thyroid-stimulating hormone, cortisol, dehydroepiandrosterone 
sulphate, and free testosterone were within normal limits. She had insulin resistance (homeostatic 
measurement assessment-insulin resistance; HOMA-IR = 3.60) but no other metabolic derangements. 
She was diagnosed of PCOS according to the revised 2003 Rotterdam criteria [14]. 
Sonohysterography was performed to investigate the suspected intrauterine lesion, and it revealed a 
polypoid mass of 1.99 × 1.31 cm in diameter. Hysteroscopy showed a polyp protruding from the fundal 
part of the uterine cavity. The mass was totally removed using an electrical loop. Histopathological 
report revealed a well-differentiated endometrioid adenocarcinoma arising in the context of atypical 
complex endometrial hyperplasia.  
The patient denied surgical staging for endometrial carcinoma. A chest X-ray and magnetic 
resonance imaging (MRI) were used to estimate the extent of the cancer. The images revealed no 
myometrial invasion, no extrauterine spreading, no enlarged pelvic or para-aortic lymph nodes, and no 
liver metastasis. The information suggested clinical stage I disease. The patient was informed about 
diagnosis and prognosis. Treatment options were discussed. She chose conservative medical treatment, 
although being aware that it was not the standard treatment.  
The patient was advised to practice lifestyle modification to reduce her weight. She was treated with 
MA 480 mg/day. Treatment response was evaluated using uterine curettage every 3 months. In spite of 
side effects, including bloating and increasing appetite, the patient agreed to continue this treatment 
regimen. By the end of treatment month 3, uterine curettage was performed and histopathology of 
endometrium still showed a well-differentiated adenocarcinoma and atypical complex hyperplasia. 
Nevertheless, the patient insisted to continue conservative treatment but asked for a treatment option 
with fewer side effects. She agreed to use a combination of LNG-IUS and a lower MA dose of 160 
mg/day. Endometrial biopsy was performed using a disposable endometrial cell sampler (Endocel, 
Wallach Surgical Devices, Inc.) at the end of treatment months 3 and 6. Histopathology of the 
endometrium of the former revealed an inactive endometrial gland with pseudodecidual change, but the 
latter revealed a tiny fragment of cytologic glandular atypia and multiple fragments of inactive 
endometrium. The dose of MA was increased to 480 mg/day. Three months later the LNG-IUS was 
removed and uterine curettage was performed under general anesthesia. Histopathology of the 
endometrium revealed scattered small fragments of inactive epithelium, pseudodecidual change of 
stroma, without hyperplasia or endometrial carcinoma. A new LNG-IUS was inserted and the MA dose 
was reduced to 160 mg/day. The patient could better tolerate this treatment regimen. We planned to 
monitor her with trimonthly ultrasonography and endometrial biopsy. There was no recurrence for at 
least 24 months after the last endometrial surveillance, which did not show any malignant endometrial 
cell.   
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Discussion 
Decision to choose conservative treatment for endometrial carcinoma needs adequate 
information, such as cellular grading, evidence of myometrial invasion and extrauterine 
spreading, and contraindications for medication. Moreover, patients have to be informed 
that the conservative treatment is not the standard treatment for this disease [3].  
Oral progestin therapy is the first choice of conservative treatment. 
Medroxyprogesterone acetate (MPA) and MA are the two most commonly used oral 
progestins. The optimal dosage is yet inconclusive. The Gynecologic Oncology Group 
states that MPA 200 mg/day is an effective dose [7]; however, a dose up to 600 mg/day has 
been reported [3]. MA 40–160 mg/day is the most frequently used medical treatment in 
the USA [15–17].
 The aforementioned oral progestin therapy had a complete response 
rate varying from 62 to 76% and a time to complete response from 3 to 9 months [3, 17, 
18]. A higher dose of oral progestin has intolerable systemic side effects, and there is no 
evidence of higher effectiveness.  
Local application of progestogen is another conservative therapeutic measure. Montz 
et al. [19] were the first to report that progesterone-intrauterine device (IUD) provided a 
complete response rate of 75% at the end of treatment month 12. Unfortunately, this 
progesterone-IUD is no longer commercially available. A novel progestin-medicated 
IUD, LNG-IUS, was shown to be effective for the prevention of endometrial hyperplasia 
in postmenopausal hormone therapy [20–22] and for the treatment of endometrial 
hyperplasia with or without atypia [23–25]. At present, 7 cases of endometrial carcinoma 
treated with LNG-IUS have been reported as summarized in table 1; 2 cases had complete 
response 5–6 months after insertion of the IUS, whereas 4 cases with persistent cancer 
had hysterectomy and the specimens showed myometrial invasion [11–13]. It is likely that 
the non-response to progestin therapy, either to local [11, 12] or oral [6] regimens, might 
be due to the pre-existing myometrial invasion. There is evidence that transvaginal 
ultrasonography and MRI may be promising tools for the evaluation of myometrial 
invasion [26, 27], therefore these tools would be valuable in case selection for conservative 
treatment. 
In the present case report, the patient was very young and wanted to preserve her 
fertility potential. Conservative treatment with progestin was considered. After high-dose 
oral MA (480 mg/day) treatment for 3 months, the endometrial carcinoma still existed. 
Since a higher dose of MA was not tolerable and had no evidence of more effectiveness, a 
combination of LNG-IUS and oral MA was provided. This combined treatment would 
theoretically deliver a higher dose of progestin to the endometrial tissue, but with less 
systemic side effects. An impressive response was observed with this combined treatment 
in our patient as the lesion was clear at treatment month 3. However, endometrial biopsy 
at treatment month 6 revealed a tiny fragment of cytological glandular atypia. Possibly, 
the endometrial biopsy performed at treatment month 3 had failed to detect the 
presumably persistent lesion. A meta-analysis shows that the sensitivity of endometrial 
biopsy to detect endometrial carcinoma is approximately 90% [28]. Therefore, the 
negative biopsy in this high-risk patient indicated the need of a more sensitive diagnostic 
tool such as endometrial curettage or hysteroscopy. In the present case, after increasing 
the MA dose to 480 mg/day in combination with LNG-IUS, histopathology of uterine 
curettage showed neither hyperplasia nor endometrial carcinoma. This was the first 
report of successful treatment of endometrial carcinoma using the combination of LNG- 
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IUS and MA. Moreover, our patient was the youngest compared with the cases in 
previous reports as summarized in table 1. Long-term management is therefore the 
challenging issue. 
The histological regression of the endometrial carcinoma in our patient was very 
encouraging. Although there exist several case reports of endometrial adenocarcinoma 
following the insertion of a LNG-IUS [29, 30], the combination of systemic progestin and 
LNG-IUS may decrease this concern. Even though patients can achieve complete 
response with conservative medical treatment, at least one third of them have recurrence 
by 20 months after cessation of treatments [3]. Therefore, prevention of recurrence is 
necessary. Potential preventive treatments include oral contraception, and cyclic or 
continuous progestins [3, 6]. In our patient, we continued the combination of LNG-IUS 
and oral progestin but with lower MA dosage (160 mg/day); this regimen has proved 
effective for 24 months until now. Optimal monitoring is yet unknown. A holistic 
approach for other problems such as obesity, metabolic abnormality, and infertility 
should also be ensured for this patient.  
In conclusion, this was the first report of successful conservative treatment of 
endometrial carcinoma in a very young, obese Asian woman using the combination of 
LNG-IUS plus oral MA. This regimen is promising for both treatment and prevention of 
recurrence. We hope that our report will give a significant contribution to this issue. 
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Table 1. Summary of reported cases of endometrial carcinoma treated with progesterone-IUD or 
LNG-IUS 
Author 
year 
reference 
No. of 
cases 
Age 
years 
Associated 
condition 
Presenting 
symptom 
Clinical staging/ 
initial histology 
 
Treatment Follow-up  response 
Montz 
et al., 
2002 
[19] 
1–12 
 
     endometrioid  carcinoma 
stage I, grade 1 
Progestasert  7 of 11 cases showed negative malignant 
endometrial cells at treatment month 6. 
6 of 8 cases showed negative malignant 
endometrial cells at treatment month 12 
1  31  morbid obesity  menorrhagia endometrial carcinoma  
stage I, grade 1 
LNG-IUS  7 months after insertion, pathological 
report of radical hysterectomy revealed 
grade 1 endometrioid carcinoma restricted 
to the endometrial mucosa 
Baha- 
mondes 
et al., 
2003 
[12] 
2 62  morbid  obesity  postmeno- 
pausal 
bleeding 
endometrial carcinoma 
stage I, grade 1 
LNG-IUS  6 months after insertion, pathological 
report of radical hysterectomy revealed 
grade 1 mixed endometrioid and mucinous 
well-differentiated adenocarcinoma with 
invasion of half of the myometrium 
Gianno- 
poulos 
et al., 
2004 
[13] 
1 78  Morbid  obesity, 
hypertension, 
coronary artery 
disease 
postmeno- 
pausal 
bleeding 
endometrial  
adenocarcinoma 
background of atypical 
hyperplasia stage I,  
grade 1  
LNG-IUS 
and MPA 
400 mg/day 
Predominantly pseudodecidualised stroma 
with small inactive glands at treatment 
month 5 
1 64  obesity,  diabetes 
mellitus 
postmeno- 
pausal 
bleeding 
endometrial  
adenocarcinoma  
background of atypical 
hyperplasia/stage I,  
grade 1  
LNG-IUS Inactive  endometrium at treatment month 
6 and remission at treatment month 36 
Dhar 
et al., 
2005 
[11] 
2 73  obesity,  diabetes 
mellitus, chronic 
lymphatic 
leukemia 
postmeno- 
pausal 
bleeding 
endometrial  
adenocarcinoma  
background of atypical 
hyperplasia/stage I,  
grade 1  
LNG-IUS  Hysterectomy was performed (at treatment 
month 6 after insertion) due to persistence 
of bleeding, histopathological report still 
showed grade 1 endometrial 
adenocarcinoma 
 3  80  obesity,  diabetes 
mellitus, multiple 
cardiovascular 
accident 
postmeno- 
pausal 
bleeding 
endometrial  
adenocarcinoma  
stage I, grade 1  
LNG-IUS  Intermittent symptom, died of pneumonia 
at month 24 after insertion 
 4  73  obesity,  diabetes 
mellitus, aortic 
stenosis, left 
brachial  
embolectomy  
postmeno- 
pausal 
bleeding 
endometrial  
adenocarcinoma  
stage I, grade 1 
LNG-IUS  Persistent of diseases at treatment month 
18, histopathological report still showed 
endometrioid adenocarcinoma 
 
 
 
References 
1  Crissman JD, Azoury RS, Barnes AE, Schellhas HF: Endometrial carcinoma in women 40 years of age or 
younger. Obstet Gynecol 1981;57:699–704. 
2  Kaku T, Matsuo K, Tsukamoto N, Shimamoto T, Sugihara K, Tsuruchi N, et al: Endometrial carcinoma in 
women aged 40 years or younger: a Japanese experience. Int J Gynecol Cancer 1993;3:147–153. 
3  Chiva L, Lapuente F, Gonzalez-Cortijo L, Carballo N, Garcia JF, Rojo A, et al: Sparing fertility in young 
patients with endometrial cancer. Gynecol Oncol 2008;111:S101–S104. 
4  Manchana T, Khemapech N: Endometrial adenocarcinoma in young Thai women. Asian Pac J Cancer Prev 
2008;9:283–286. 
5  Balen A: Polycystic ovary syndrome and cancer. Hum Reprod Update 2001;7:522–525. 
6  Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C: Hormonal therapy for the management of 
grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133–138.  
Case Rep Oncol 2010;3:380–385 
DOI: 10.1159/000321731 
Published online: 
October 25, 2010 
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
385
7  Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, et al: Oral medroxyprogesterone 
acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the 
Gynecologic Oncology Group. J Clin Oncol 1999;17:1736–1744. 
8  Topuz S, Kalelioglu I, Iyibozkurt C, Ergun B: Conservative management of a patient with endometrial 
carcinoma desiring fertility: how to inform? Eur J Gynaecol Oncol 2008;29:661–663. 
9  Wang HY, Shen L, Sun Z: [Endometrial adenocarcinoma in women 40 years old or younger by treatment with 
progestins: report of 6 cases and review of the literatures]. Zhonghua Fu Chan Ke Za Zhi 2006;41:237–241. 
10  Geisler HE, Huber CP, Rogers S: Carcinoma of the endometrium in premenopausal women. Am J Obstet 
Gynecol 1969;104:657–663. 
11  Dhar KK, NeedhiRajan T, Koslowski M, Woolas RP: Is levonorgestrel intrauterine system effective for 
treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 
2005;97:924–927. 
12  Bahamondes L, Ribeiro-Huguet P, de Andrade KC, Leon-Martins O, Petta CA: Levonorgestrel-releasing 
intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol 
Scand 2003;82:580–582. 
13  Giannopoulos T, Butler-Manuel S, Tailor A: Levonorgestrel-releasing intrauterine system (LNG-IUS) as a 
therapy for endometrial carcinoma. Gynecol Oncol 2004;95:762–764. 
14  Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome 
(PCOS). Hum Reprod 2004;19:41–47. 
15  Kowalczyk CL, Malone J Jr, Peterson EP, Jacques SM, Leach RE: Well-differentiated endometrial 
adenocarcinoma in an infertility patient with later conception. A case report. J Reprod Med 1999;44:57–60. 
16  Lowe MP, Bender D, Sood AK, Davis W, Syrop CH, Sorosky JI: Two successful pregnancies after conservative 
treatment of endometrial cancer and assisted reproduction. Fertil Steril 2002;77:188–189. 
17  Randall TC, Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the 
endometrium in women under age 40. Obstet Gynecol 1997;90:434–440. 
18  Kim YB, Holschneider CH, Ghosh K, Nieberg RK, Montz FJ: Progestin alone as primary treatment of 
endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer 
1997;79:320–327. 
19  Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ: Intrauterine progesterone treatment of early 
endometrial cancer. Am J Obstet Gynecol 2002;186:651–657. 
20  Andersson K, Mattsson LA, Rybo G, Stadberg E: Intrauterine release of levonorgestrel – a new way of adding 
progestogen in hormone replacement therapy. Obstet Gynecol 1992;79:963–967. 
21  Boon J, Scholten PC, Oldenhave A, Heintz AP: Continuous intrauterine compared with cyclic oral progestin 
administration in perimenopausal HRT. Maturitas 2003;46:69–77. 
22  Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen F, Ronni-Sivula H, et al: Intrauterine 10 microg 
and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement 
therapy: clinical, endometrial and metabolic response. Bjog 2002;109:136–144. 
23  Wildemeersch D, Dhont M: Treatment of nonatypical and atypical endometrial hyperplasia with a 
levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2003;188:1297–1298. 
24  Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A: Nuclear morphometric changes and therapy monitoring 
in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic 
medroxyprogesterone. Gynecol Oncol 2003;91:526–533. 
25  Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, et al: The effectiveness of a levonorgestrel-
releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia – a long-term follow-up 
study. Eur J Obstet Gynecol Reprod Biol 2008;139:169–175. 
26  Saez F, Urresola A, Larena JA, Martin JI, Pijuan JI, Schneider J, et al: Endometrial carcinoma: assessment of 
myometrial invasion with plain and gadolinium-enhanced MR imaging. J Magn Reson Imaging 2000;12:460–
466. 
27  Zarbo G, Caruso G, Caruso S, Mangano U, Zarbo R: Endometrial cancer: preoperative evaluation of 
myometrial infiltration magnetic resonance imaging versus transvaginal ultrasonography. Eur J Gynaecol 
Oncol 2000;21:95–97. 
28  Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP: The accuracy of endometrial sampling in the diagnosis of 
patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer 2000;89:1765–1772. 
29  Abu J, Brown L, Ireland D: Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing 
intrauterine system (Mirena) in a 36-year-old woman. Int J Gynecol Cancer 2006;16:1445–1447. 
30  Flemming R, Sathiyathasan S, Jackson A: Endometrioid adenocarcinoma after insertion of a levonorgestrel-
releasing intrauterine system. J Minim Invasive Gynecol 2008;15:771–773. 